The trial involving 348 samples (200 women with
ovarian cancer and 148 controls) found the test to have both high specificity (87%) and high sensitivity
(90%), with a high overall Receiver Operating Characteristic (ROC)-Area Under the Curve (AUC) score
for accuracy of 0.92. In addition, the test detected all subtypes and stages of ovarian cancer in the samples
with the performance of the test between early-stage and late stage ovarian cancer not statistically different
(p>0.5).
The BARD1 Ova
This will put them on the map for sure!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $40.74M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 36.0¢ | $24.01K | 65.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 39134 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 7500 | 1 |
View Market Depth
| Last trade - 15.45pm 29/07/2025 (20 minute delay) ? |
| IIQ (ASX) Chart |